A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults with Compensated Chronic Hepatitis B

Investigator: Mandana Khalili, MD
Sponsor: Idenix Pharmaceuticals, Inc.

Location(s): United States


This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the treatment of hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking Lamivudine.